Fig. 4: Competitive disadvantage of wild-type ISCs was lost upon combinatory inhibition on GSK-3β and BCL-XL. | Oncogenesis

Fig. 4: Competitive disadvantage of wild-type ISCs was lost upon combinatory inhibition on GSK-3β and BCL-XL.

From: GSK-3 and BCL-XL inhibition mitigates the competitive advantage of APC-mutant colorectal cancer cells

Fig. 4

A Schematic illustration of the setting of co-culture assay. B Representative images of the time course co-culture experiment. Co-cultures were treated with or without 10 µM CHIR-99021. Pictures were captured at 4× magnification on Days 1, 3, and 7 after treatment. C Representative images of the co-cultures treated with 5 or 10 µM CHIR-99021 with or/and 1, 2.5, 5 µM A-1155463. Pictures were captured at 4× magnification at Day 7 after treatment. D Statistics of the relative surface contribution of wild-type organoids (Red) and APC-mutant organoids (Green). E Mechanistic Illustration of the synergistic effect of combination of GSK-3β inhibitor and BCL-XL inhibitor on the competition between WT and APC-mutant ISCs.

Back to article page